

Covid-19 External Quality Assessment

UK NEQAS are pleased to offer EQA programmes for laboratories when diagnosing, treating and monitoring Covid-19.

Covid-19 Diagnostic Programmes

SARS-CoV-2 Antibody Tests

SARS-CoV-2 Molecular Tests

Troponin (1, 2, 3)

Treatment and Monitoring Programmes

- APTT (2)
- B-Type Natriuretic Peptide (BNP) (3, 4)
- C-Reactive Protein (2)
- D-Dimer Assay (2)
- Ferritin (2, 5)
- Fibrinogen (2)
- Full Blood Count (2)
- HIT Screening (6)
- Interleukin-6 (3, 7)
- Monitoring anticoagulation with LMWH & UFH (8)
- NT-proBNP (4)
- Procalcitonin (2)
- Prothrombin Time (2)
- Routine Biochemistry (5)
- Troponin (1, 2, 3)

Educational Modules

(suitable for all who work in laboratories receiving & processing SARS-CoV-2 Virus samples, primarily aimed at non-NHS staff)

- Individual Competency Assessment for Covid-19 Testing
- Individual Competency Assessment for Covid-19 Swabbing

ENQUIRE NOW:

E: centraloffice@ukneqas.org

T: +44 (0) 114 2611689

Covid-19 External Quality Assessment

Reference List

1. Chapman, A.R., Bularga, A. and Mills, N.L. (2020). High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. *Circulation*. Available at: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047008> Accessed 20 May 2020
2. Favalaro, E.J. and Lippi, G. (2020). Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring. *Seminars in Thrombosis and Hemostasis*, 46(03), pp.379–382
3. O'Neill, A. (2020). troponin and IL-6 levels associated with poor prognosis in COVID-19. [online] *Cardiac Rhythm News*. Available at: <https://cardiacrhythmnews.com/raised-troponin-and-interleukin-6-levels-are-associated-with-a-poor-prognosis-in-covid-19/> [Accessed 24 Apr. 2020].
4. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis [published online ahead of print, 2020 Apr 10]. *Clin Chem Lab Med*. 2020;:/j/cclm.ahead-of-print/cclm-2020-0369/cclm-2020-0369.xml. doi:10.1515/cclm-2020-0369
5. Liu, P.P., Blet, A., Smyth, D. and Li, H. (2020). The Science Underlying COVID-19: Implications for the Cardiovascular System. *Circulation*. Available at: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047549> | Accessed 20 May 2020
6. Jing-Chun Song et al (2020). Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. *Mill Med Res*; 7: p19
7. Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet*, [online] 395(10229), pp.1033–1034. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30628-0/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext).
8. Tang N et al (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost.* ;18(5):pp1094-109

ENQUIRE NOW:

E: centraloffice@ukneqas.org

T: +44 (0) 114 2611689